Cargando…

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Background: Natalizumab (NAT) is a high-efficacy treatment for relapsing remitting multiple sclerosis (RRMS). However, it is associated with an increased risk of progressive multifocal leukoencephalopathy that sometimes requires treatment cessation with a risk of returning disease activity. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Proschmann, Undine, Inojosa, Hernan, Akgün, Katja, Ziemssen, Tjalf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079654/ https://www.ncbi.nlm.nih.gov/pubmed/33935948 http://dx.doi.org/10.3389/fneur.2021.650530

Ejemplares similares

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
por: Proschmann, Undine, et al.
Publicado: (2021)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Should We Use Clinical Tools to Identify Disease Progression?
por: Inojosa, Hernan, et al.
Publicado: (2021)

Influence of exercise on quantity and deformability of immune cells in multiple sclerosis
por: Proschmann, Undine, et al.
Publicado: (2023)

The need for a strategic therapeutic approach: multiple sclerosis in check
por: Inojosa, Hernan, et al.
Publicado: (2022)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication
por: Inojosa, Hernan, et al.
Publicado: (2023)

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
por: Akgün, Katja, et al.
Publicado: (2019)

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
por: Fischer, Stefanie, et al.
Publicado: (2021)

Balance Testing in Multiple Sclerosis—Improving Neurological Assessment With Static Posturography?
por: Inojosa, Hernan, et al.
Publicado: (2020)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Influence of Pre-Analytic Conditions on Quantity of Lymphocytes
por: Proschmann, Undine, et al.
Publicado: (2023)

Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients
por: Nötzel, Martin, et al.
Publicado: (2022)

Digital Twins for Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2021)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies
por: Sehr, T., et al.
Publicado: (2016)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study
por: Häusler, Darius, et al.
Publicado: (2021)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Digital Biomarkers in Multiple Sclerosis
por: Dillenseger, Anja, et al.
Publicado: (2021)

Visual Feedback and Postural Control in Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

Management of multiple sclerosis fatigue in the digital age: from assessment to treatment
por: Pinarello, Chiara, et al.
Publicado: (2023)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Pilot study on the influence of acute alcohol exposure on biophysical parameters of leukocytes
por: Shalchi-Amirkhiz, Puya, et al.
Publicado: (2023)

Data Collection in Multiple Sclerosis: The MSDS Approach
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis
por: Kim, Ki Hoon, et al.
Publicado: (2021)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children
por: Nitz, Elisa, et al.
Publicado: (2021)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies
por: Saak, Annika, et al.
Publicado: (2021)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
por: Sehr, Tony, et al.
Publicado: (2020)

A Digital Patient Portal for Patients With Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2020)

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
por: Woopen, Christina, et al.
Publicado: (2021)

CSF and Serum Biomarkers of Cerebral Damage in Autoimmune Epilepsy
por: Nass, Robert Daniel, et al.
Publicado: (2021)

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
por: Varhaug, Kristin N., et al.
Publicado: (2019)

Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT(®) Autoinjector: A Prospective Observational Cohort Study
por: Köhler, Wolfgang, et al.
Publicado: (2021)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
por: Guger, Michael, et al.
Publicado: (2020)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_52c8pvv4dpage0qrfkjcmpccp5